Biocon Ltd said its generic version of Roche's Herceptin breast cancer treatment drug would be available to patients in India from the first week of February.
Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with US-based Mylan Inc.
About 150,000 people are diagnosed with breast cancer every year in India, of which 25 per cent are eligible for treatment with trastuzumab, Biocon said.
Roche decided not to pursue a patent application for its breast cancer drug Herceptin in India, paving the way for generic drug makers to produce cheaper copies, known as biosimilars because they are not identical to the original drug.
Global sales for Herceptin were valued at about $6.4 billion in 2012, including about $21 million in India, Biocon said.
Copyright @ Thomson Reuters 2014
Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.